BioWorld

March 14, 2005

View Archived Issues

Savient Terminates Phase II Prosaptide Analgesia Study

Savient Pharmaceuticals Inc. has halted its Phase II trial for Prosaptide after an interim analysis indicated the product would not reach its analgesia efficacy endpoint. (BioWorld Today) Read More

XOMA Anti-Terrorism Deal Provides Needed Stock Hike

Read More

Survival Of Fittest In 2005 For Biotechnology Firms

Read More

Raising $7M, ImaRx Plans To Fund Trials, Add Executives

Read More

Republicans, Democrats Detail Health Care Agendas For 2005

Read More

Other News To Note

Read More

Appointments And Advancements

Read More